Table 3.
aracteristics of participants in warfarin reversal cohort by eGFR categorya
| Characteristic | eGFR>60 (n=39) | eGFR=45–59 (n=15) | eGFR=30–44 (n=7) | eGFR<30 (n=13) | P trend b |
|---|---|---|---|---|---|
| Age (y) | 57.9 ± 18.9 | 64.3 ± 16.5 | 58.0 ± 15.4 | 69.9 ± 14.5 | 0.1 |
| BMI (kg/m2) | 27.4 ± 5.7 | 26.0 ± 9.5 | 29.4 ± 2.9 | 27.8 ± 7.7 | 0.5 |
| INR at visit 1 | 7.4 ± 2.5 | 6.5 ± 2.3 | 6.1 ± 2.0 | 6.6 ± 2.3 | 0.3 |
| INR at visit 2 | 2.6 ± 1.2 | 3.0 ± 1.0 | 1.8 ± 0.8 | 2.9 ± 1.7 | 0.8 |
| Difference in INR* | 4.8 ± 2.6 | 3.5 ± 1.6 | 4.2 ± 2.2 | 3.7 ± 1.9 | 0.3 |
| Warfarin dose (mg/wk) | 38.4 ± 20.7 | 35.6 ± 15.4 | 30.4 ± 11.7 | 31.5 ± 11.6 | 0.2 |
| Time between visits 1 and 2 (h) | 33.3 [23.3–65.0] | 42.5 [23.7–66.3] | 43.0 [23.3 – 73.9] | 39.4 [22.0–74.8] | 0.9 |
| Vitamin K dose (mg) | 4.8 ± 3.5 | 6.3 ± 3.4 | 2.8 ± 1.5 | 6.6 ± 3.8 | 0.7 |
|
| |||||
| Female sex | 21 (54) | 6 (40) | 3 (43) | 10 (77) | 0.3 |
| African American | 15 (39) | 8 (53) | 2 (29) | 8 (62) | 0.3 |
| Receiving vitamin K | 22 (56) | 7 (47) | 4 (57) | 10 (77) | 0.3 |
| Indication for Warfarin therapy | |||||
| Venous thromboembolism | 20 (51) | 3 (20) | 4 (57) | 7 (54) | |
| Stroke /TIA | 1 (3) | 1 (7) | 0 (0) | 0 (0) | |
| Atrial Fibrillation | 12 (31) | 5 (33) | 3 (43) | 3 (23) | |
| Otherc | 6 (15) | 6 (40) | 0 (0) | 3 (23) | |
| Genotyped | |||||
| CYP2C9 variant | 7 (18) | 1 (7) | 2 (29) | 1 (8) | 0.5 |
| VKORC1 variant | 21 (55) | 7 (47) | 5 (71) | 6 (46) | 0.8 |
| CYP4F2 variant | 10 (26) | 3 (21) | 2 (29) | 3 (23) | 0.9 |
| GGCX variant | 4 (11) | 1 (7) | 1 (14) | 1 (8) | 0.9 |
BMI, body mass index; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; rs, reference single-nulceotide polymorphism identification number;TIA, transient ischemic attack
value at visit 2 less the value at visit 1
Note: All patients on warfarin therapy with target INR of 2–3 were being treated to reverse elevated INR levels by withholding warfarin with or without supplemental vitamin K. Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range]. eGFR categrories expressed in ml/min/1.73m2.
p is significant at α =0.05 and denote differences across kidney function categories; p-values for continuous variables derived from Kruskal-Wallis test; p-values for categorical variables derived from Chi-Square Test.
other indications include cardiac thrombus, myocardial infarction, peripheral vascular disease, etc.
see notes to Table 1.